Hospices Civils de Lyon, Groupement Hospitalier Sud, Clinical Oncology Pharmacy Department - Université Lyon 1, Ecole Doctorale Interdisciplinaire Sciences Santé, Lyon, France.
Eur J Cancer. 2012 May;48(8):1192-9. doi: 10.1016/j.ejca.2011.12.031. Epub 2012 Jan 28.
The majority of medication errors that harm patients relate to the prescribing process. Our study aimed to identify the predictors of prescription errors involving anticancer chemotherapy agents.
All consecutive antineoplastic prescriptions from June 2006 to May 2008 were analysed, with medication errors being captured. Potential risk factors for medication prescribing errors were defined in relation to the patient, chemotherapy regimen and hospital organisation. The relationship between these risk factors and observed medication errors or dose medication errors was assessed by univariate and multivariate logistic-regression analyses.
Among the 17,150 chemotherapy prescriptions, 540 contained at least one error (3.15%). The following independent predictors of risk of medication errors were identified: patients with a body surface area >2m(2) (odds ratio (OR): 1.3, 95% confidence interval (CI) 1.01-1.67, p=0.04), protocols with more than three drugs (OR: 1.91, 95%CI 1.59-2.31, p<0.001), protocols involving carboplatin (OR: 2.33, 95%CI 1.85-2.95, p<0.001), protocols requiring at least one modification by the physician (OR: 1.32, 95%CI 1.09-1.61, p=0.005), inpatient care (OR: 1.58, 95%CI 1.28-1.93, p<0.001) and prescriptions by a resident physician (OR: 1.83, 95%CI 1.50-2.22, p<0.001). The risk of medication dose prescribing errors was significantly associated with three independent factors: protocols involving carboplatin (OR: 4.47, 95%CI 3.45-5.79, p<0.001), protocols with more than three drugs (OR: 2.4, 95%CI 1.92-3.00, p<0.001) and protocols requiring at least one modification (OR: 1.33, 95%CI 1.04-1.69, p=0.02).
In this epidemiologic study, the independent risk factors identified should be targeted for preventive measures in order to improve anticancer agent prescriptions and reduce the risk of medication errors.
大多数对患者造成伤害的用药错误与处方过程有关。我们的研究旨在确定涉及抗癌化疗药物的处方错误的预测因素。
分析 2006 年 6 月至 2008 年 5 月所有连续的抗肿瘤处方,捕捉药物错误。与患者、化疗方案和医院组织有关的药物处方错误的潜在危险因素被定义。通过单变量和多变量逻辑回归分析评估这些危险因素与观察到的药物错误或剂量药物错误之间的关系。
在 17150 例化疗处方中,有 540 例含有至少 1 个错误(3.15%)。确定了以下药物错误风险的独立预测因素:体表面积>2m²的患者(比值比(OR):1.3,95%置信区间(CI)1.01-1.67,p=0.04)、含有超过三种药物的方案(OR:1.91,95%CI 1.59-2.31,p<0.001)、含卡铂的方案(OR:2.33,95%CI 1.85-2.95,p<0.001)、至少需要医生修改一次的方案(OR:1.32,95%CI 1.09-1.61,p=0.005)、住院治疗(OR:1.58,95%CI 1.28-1.93,p<0.001)和住院医师处方(OR:1.83,95%CI 1.50-2.22,p<0.001)。药物剂量处方错误的风险与三个独立因素显著相关:含卡铂的方案(OR:4.47,95%CI 3.45-5.79,p<0.001)、含有三种以上药物的方案(OR:2.4,95%CI 1.92-3.00,p<0.001)和至少需要修改一次的方案(OR:1.33,95%CI 1.04-1.69,p=0.02)。
在这项流行病学研究中,确定的独立危险因素应作为预防措施的目标,以改善抗癌药物处方,降低用药错误风险。